Literature DB >> 28129123

Improved Intravitreal AAV-Mediated Inner Retinal Gene Transduction after Surgical Internal Limiting Membrane Peeling in Cynomolgus Monkeys.

Kazuhisa Takahashi1, Tsutomu Igarashi1, Koichi Miyake2, Maika Kobayashi3, Chiemi Yaguchi3, Osamu Iijima4, Yoshiyuki Yamazaki4, Yuko Katakai5, Noriko Miyake4, Shuhei Kameya6, Takashi Shimada4, Hiroshi Takahashi3, Takashi Okada4.   

Abstract

The retina is an ideal target for gene therapy because of its easy accessibility and limited immunological response. We previously reported that intravitreally injected adeno-associated virus (AAV) vector transduced the inner retina with high efficiency in a rodent model. In large animals, however, the efficiency of retinal transduction was low, because the vitreous and internal limiting membrane (ILM) acted as barriers to transduction. To overcome these barriers in cynomolgus monkeys, we performed vitrectomy (VIT) and ILM peeling before AAV vector injection. Following intravitreal injection of 50 μL triple-mutated self-complementary AAV serotype 2 vector encoding EGFP, transduction efficiency was analyzed. Little expression of GFP was detected in the control and VIT groups, but in the VIT+ILM group, strong GFP expression was detected within the peeled ILM area. To detect potential adverse effects, we monitored the retinas using color fundus photography, optical coherence tomography, and electroretinography. No serious side effects associated with the pretreatment were observed. These results indicate that surgical ILM peeling before AAV vector administration would be safe and useful for efficient transduction of the nonhuman primate retina and provide therapeutic benefits for the treatment of retinal diseases.
Copyright © 2017 The American Society of Gene and Cell Therapy. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  cynomolgus; glaucoma; internal limiting membrane; intravitreous injection; retina; triple-mutated AAV

Mesh:

Year:  2017        PMID: 28129123      PMCID: PMC5363307          DOI: 10.1016/j.ymthe.2016.10.008

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  27 in total

1.  ISCEV Standard for full-field clinical electroretinography (2008 update).

Authors:  M F Marmor; A B Fulton; G E Holder; Y Miyake; M Brigell; M Bach
Journal:  Doc Ophthalmol       Date:  2008-11-22       Impact factor: 2.379

2.  Gene delivery to the retina: from mouse to man.

Authors:  Jean Bennett; Daniel C Chung; Albert Maguire
Journal:  Methods Enzymol       Date:  2012       Impact factor: 1.600

3.  The staining pattern of brilliant blue G during macular hole surgery: a clinicopathologic study.

Authors:  David H W Steel; Christiana Dinah; Haifa A Madi; Haifa Magdi; Kathryn White; Jon Rees
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-08-14       Impact factor: 4.799

4.  Gene therapy with recombinant adeno-associated vectors for neovascular age-related macular degeneration: 1 year follow-up of a phase 1 randomised clinical trial.

Authors:  Elizabeth P Rakoczy; Chooi-May Lai; Aaron L Magno; Matthew E Wikstrom; Martyn A French; Cora M Pierce; Steven D Schwartz; Mark S Blumenkranz; Thomas W Chalberg; Mariapia A Degli-Esposti; Ian J Constable
Journal:  Lancet       Date:  2015-09-30       Impact factor: 79.321

5.  Dissociated optic nerve fiber layer appearance after internal limiting membrane peeling for idiopathic macular holes.

Authors:  Yasuki Ito; Hiroko Terasaki; Akiko Takahashi; Tomomi Yamakoshi; Mineo Kondo; Makoto Nakamura
Journal:  Ophthalmology       Date:  2005-08       Impact factor: 12.079

6.  "Dissociated optic nerve fiber layer appearance" after internal limiting membrane removal is inner retinal dimpling.

Authors:  Richard F Spaide
Journal:  Retina       Date:  2012-10       Impact factor: 4.256

Review 7.  Early and late inner retinal changes after inner limiting membrane peeling.

Authors:  Francesco Pichi; Andrea Lembo; Mariachiara Morara; Chiara Veronese; Micol Alkabes; Paolo Nucci; Antonio P Ciardella
Journal:  Int Ophthalmol       Date:  2013-07-18       Impact factor: 2.031

8.  Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trial.

Authors:  Albert M Maguire; Katherine A High; Alberto Auricchio; J Fraser Wright; Eric A Pierce; Francesco Testa; Federico Mingozzi; Jeannette L Bennicelli; Gui-shuang Ying; Settimio Rossi; Ann Fulton; Kathleen A Marshall; Sandro Banfi; Daniel C Chung; Jessica I W Morgan; Bernd Hauck; Olga Zelenaia; Xiaosong Zhu; Leslie Raffini; Frauke Coppieters; Elfride De Baere; Kenneth S Shindler; Nicholas J Volpe; Enrico M Surace; Carmela Acerra; Arkady Lyubarsky; T Michael Redmond; Edwin Stone; Junwei Sun; Jennifer Wellman McDonnell; Bart P Leroy; Francesca Simonelli; Jean Bennett
Journal:  Lancet       Date:  2009-10-23       Impact factor: 79.321

9.  Inner limiting membrane barriers to AAV-mediated retinal transduction from the vitreous.

Authors:  Deniz Dalkara; Kathleen D Kolstad; Natalia Caporale; Meike Visel; Ryan R Klimczak; David V Schaffer; John G Flannery
Journal:  Mol Ther       Date:  2009-08-11       Impact factor: 11.454

10.  Retinal gene therapy in patients with choroideremia: initial findings from a phase 1/2 clinical trial.

Authors:  Robert E MacLaren; Markus Groppe; Alun R Barnard; Charles L Cottriall; Tanya Tolmachova; Len Seymour; K Reed Clark; Matthew J During; Frans P M Cremers; Graeme C M Black; Andrew J Lotery; Susan M Downes; Andrew R Webster; Miguel C Seabra
Journal:  Lancet       Date:  2014-01-16       Impact factor: 79.321

View more
  28 in total

1.  AAV8-vectored suprachoroidal gene transfer produces widespread ocular transgene expression.

Authors:  Kun Ding; Jikui Shen; Zibran Hafiz; Sean F Hackett; Raquel Lima E Silva; Mahmood Khan; Valeria E Lorenc; Daiqin Chen; Rishi Chadha; Minie Zhang; Sherri Van Everen; Nicholas Buss; Michele Fiscella; Olivier Danos; Peter A Campochiaro
Journal:  J Clin Invest       Date:  2019-08-13       Impact factor: 14.808

2.  Retina transduction by rAAV2 after intravitreal injection: comparison between mouse and rat.

Authors:  Mariana S Dias; Victor G Araujo; Taliane Vasconcelos; Qiuhong Li; William W Hauswirth; Rafael Linden; Hilda Petrs-Silva
Journal:  Gene Ther       Date:  2019-09-27       Impact factor: 5.250

3.  Noninvasive gene delivery to foveal cones for vision restoration.

Authors:  Hanen Khabou; Marcela Garita-Hernandez; Antoine Chaffiol; Sacha Reichman; Céline Jaillard; Elena Brazhnikova; Stéphane Bertin; Valérie Forster; Mélissa Desrosiers; Céline Winckler; Olivier Goureau; Serge Picaud; Jens Duebel; José-Alain Sahel; Deniz Dalkara
Journal:  JCI Insight       Date:  2018-01-25

4.  Gene Therapy Targeting the Inner Retina Rescues the Retinal Phenotype in a Mouse Model of CLN3 Batten Disease.

Authors:  Sophia-Martha Kleine Holthaus; Mikel Aristorena; Ryea Maswood; Olha Semenyuk; Justin Hoke; Aura Hare; Alexander J Smith; Sara E Mole; Robin R Ali
Journal:  Hum Gene Ther       Date:  2020-07       Impact factor: 5.695

5.  Fundus imaging of retinal ganglion cells transduced by retrograde transport of rAAV2-retro.

Authors:  Rakesh Nanjappa; Mikayla D Dilbeck; John R Economides; Jonathan C Horton
Journal:  Exp Eye Res       Date:  2022-04-20       Impact factor: 3.770

Review 6.  The internal limiting membrane: Roles in retinal development and implications for emerging ocular therapies.

Authors:  Kevin Y Zhang; Thomas V Johnson
Journal:  Exp Eye Res       Date:  2021-03-20       Impact factor: 3.467

Review 7.  Clinical Perspective: Treating RPE65-Associated Retinal Dystrophy.

Authors:  Albert M Maguire; Jean Bennett; Elena M Aleman; Bart P Leroy; Tomas S Aleman
Journal:  Mol Ther       Date:  2020-12-03       Impact factor: 11.454

8.  Toward smart design of retinal drug carriers: a novel bovine retinal explant model to study the barrier role of the vitreoretinal interface.

Authors:  Karen Peynshaert; Joke Devoldere; Valérie Forster; Serge Picaud; Christian Vanhove; Stefaan C De Smedt; Katrien Remaut
Journal:  Drug Deliv       Date:  2017-11       Impact factor: 6.419

Review 9.  Delivering AAV to the Central Nervous and Sensory Systems.

Authors:  Cole W Peters; Casey A Maguire; Killian S Hanlon
Journal:  Trends Pharmacol Sci       Date:  2021-04-13       Impact factor: 17.638

Review 10.  Translating CRISPR-Cas Therapeutics: Approaches and Challenges.

Authors:  Lavina Sierra Tay; Nathan Palmer; Rebecca Panwala; Wei Leong Chew; Prashant Mali
Journal:  CRISPR J       Date:  2020-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.